Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis
Master Thesis
2013
Permanent link to this Item
Authors
Journal Title
Link to Journal
Journal ISSN
Volume Title
Publisher
Publisher
University of Cape Town
Department
Faculty
License
Series
Abstract
Sub-Saharan Africa is overwhelmed by dual epidemics of human immunodeficiency virus (HIV) and tuberculosis (TB) infection. Non-nucleoside reverse-transcriptase inhibitor (NNRTI)-based antiretroviral therapy (ART) is recommended for first-line treatment in adult HIV treatment programmes in resource-limited settings [1]. Many South African HIV-infected patients initiate ART while on TB treatment, 38 percent in one local study [2]. In addition, although ART reduces the incidence of TB, incidence in patients on ART is higher than in the HIV uninfected population [3], therefore incident TB on ART requiring concomitant treatment is very common. Efavirenz is regarded as the NNRTI of choice for TB co-infected patients [1] as outcomes are superior compared to those achieved with nevirapine-based ART [4] and concomitant TB treatment does not significantly reduce efavirenz concentrations [5]. However nevirapine is cheaper than efavirenz and is used extensively used in lower income countries with limited access to efavirenz [1]. Data characterising the extent to which concomitant rifampicin-based TB treatment decreases nevirapine plasma concentration therefore remain important.
Description
Includes bibliographical references.
Keywords
Reference:
Cohen, K. 2013. Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis. University of Cape Town.